AltMed Florida is offering medical cannabis patients access to the HIPAA compliant Strainprint™ App for free download at https://strainprint.ca/altmedmuv/. Strainprint is the leading customized tracking, monitoring and reporting app, designed to anonymously share patient experiences to improve outcomes for the Florida medical cannabis community.
Deemed an essential service under the Florida Stay-at-Home directive, MÜV Dispensaries across the state have experienced high demand during the COVID-19 crisis. While at home, patients are embracing the Strainprint technology that allows them to examine what works best and share feedback with the broader community so patients can learn from each other.
“With limited access to clinical trials, Strainprint provides a rare glimpse into data shared by patients who report which types of medical cannabis products produce the best results,” said AltMed Director of Corporate Affairs Todd Beckwith. “For example - a patient could try a 1:1 THC/CBD tincture to treat a specific symptom and using the app they receive an alert prompting them to rate from 1-to-10 how they feel after a certain amount of time. This data is then pooled together with other anonymous users’ feedback so patients can learn what has worked well for others treating the same symptom.”
Patients input and track personal usage information including:
Patients can then review and adjust based on which strains, THC + CBD levels, methods and dosages work well for their symptoms. They can also compare which strains are ranked highest in efficacy by other anonymous patients in Strainprint’s extensive database, which includes over two million data points from patients in legal jurisdictions across the U.S. and Canada.
“In our tireless efforts to serve Floridians, we’re excited to offer our patients access to this intuitive app,” Beckwith said.
As a science-driven company, AltMed will also monitor patient data from the app to learn which products and terpene levels are working best for certain conditions and adapt by developing new products.
To access the Strainprint MÜV by AltMed Florida Edition visit https://strainprint.ca/altmedmuv/. To populate MÜV products for ease of tracking, use activation code “MUVFL”.
To order online for express pickup or delivery and for more information including hours and available MÜV products, visit muvfl.com.
With 18 dispensaries open to date, AltMed Florida is on pace to open 40 MÜV Medical Cannabis dispensaries across the state, all supplied by its 200,000-square-foot, state-of-the-art cultivation facility.
The MÜV™ brand of medical cannabis infused products launched in Arizona in 2016 and quickly gained international attention and recognition. MÜV Dispensaries by AltMed Florida was formed a year later through the partnership of AltMed Enterprises and Plants of Ruskin, a multi-generational Florida agricultural leader. Through continual research and development, MÜV has received multiple patents for its award-winning MÜV Products line that provides quality, consistent and reliable medical cannabis products to patients at all 29 locations (one in Arizona muv-az.com, 28 in Florida muvfl.com, and more added each month). Patients are encouraged to place reservations online at muvfl.com for in-store pickup, order for delivery, or visit any one of the 27 MÜV Dispensaries for alternative medical cannabis medicine you can trust.
With a focus on quality and attention to detail, Plants of Ruskin has more than 35 years of experience in providing seedlings to farmers for vegetable and medical product production. Plants of Ruskin founders, the Dickman Family, are 4th generation farmers with a long history of working in conjunction with the University of Florida, including an endowed chair specifically dedicated to plant improvement.
Alternative Medical Enterprises, LLC, headquartered in Sarasota, FL and doing business as AltMed Enterprises, is a fully integrated medical cannabis company that brings compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabinoids.
Forward-Looking Statements - To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking in nature and merely express our beliefs, expectations or opinions. For example, words such as “may,” “should,” “estimates,” “predicts,” “continues,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” “strategy” and similar expressions are intended to identify forward-looking statements. Such statements are based on current expectations or estimates and involve a number of known and unknown risks and uncertainties that could cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the following: (i) our ability to implement our business strategy of distributing high quality cannabis products where permissible under applicable law; (ii) availability and cost of additional capital; (iii) our ability to attract, retain and motivate qualified employees and management; (iv) the impact of federal, state or local government regulations; (v) competition in the cannabis industry; (vi) our ability to generate revenues; and (vii) litigation in connection with our business. All forward-looking statements included in this press release and attributable to us or any person acting on our behalf are qualified by this cautionary statement. Forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.